3
项与 Pegylated GLP-1 analogue (LY2428757) -(Eli Lilly & Co.) 相关的临床试验Ensayo en doble ciego y controlado con placebo, de 12 semanas de duración, de LY2428757 en pacientes con diabetes mellitus de tipo 2.A 12-Week, Double-Blind, Placebo-Controlled Trial of LY2428757 in Patients with Type 2 Diabetes Mellitus
A Proof of Concept Study to Evaluate the Coadministration of TT223 Given Daily and LY2428757 Given Once-Weekly for Four Weeks in Patients With Type 2 Diabetes Mellitus
Test the safety, tolerability and improvement of blood sugar control with combination therapy in individuals with Type 2 Diabetes.
A 12-Week,Double-Blind, Placebo-Controlled Trial of LY2428757 in Patients With Type 2 Diabetes Mellitus
A multicenter, multinational, randomized,double-blind, placebo-controlled study in patients with Type 2 Diabetes Mellitus (T2DM). Patients with inadequate glycemic control using diet and exercise alone, or in combination with metformin, will be enrolled. The primary objective of this study is to test the hypothesis that LY2428757 given to patients with T2DM inadequately controlled with diet and exercise alone, or metformin monotherapy, produces a significant decrease in the mean hemoglobin A1c (HbA1c) from baseline to endpoint at 12 weeks as compared to placebo. Trial consists of 12 weeks of double-blind treatment and 4-week safety follow-up.
100 项与 Pegylated GLP-1 analogue (LY2428757) -(Eli Lilly & Co.) 相关的临床结果
100 项与 Pegylated GLP-1 analogue (LY2428757) -(Eli Lilly & Co.) 相关的转化医学
100 项与 Pegylated GLP-1 analogue (LY2428757) -(Eli Lilly & Co.) 相关的专利(医药)
100 项与 Pegylated GLP-1 analogue (LY2428757) -(Eli Lilly & Co.) 相关的药物交易